Randomized Phase II Trial of Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: The CheckPRO, CA209-8TY Trial

0
5
Scientists hypothesized that the addition of stereotactic body radiation therapy could enhance immune responses and improve treatment outcomes.
[Journal for Immunotherapy of Cancer]
Full Article